Total Payments
$8,722
2024 Payments
$674.15
Companies
41
Transactions
553
Medicare Patients
8,444
Medicare Billing
$2.1M
Payment Breakdown by Category
Food & Beverage$8,053 (92.3%)
Education$544.65 (6.2%)
Other$125.00 (1.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,053 | 512 | 92.3% |
| Education | $544.65 | 40 | 6.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $125.00 | 1 | 1.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $1,169 | 64 | $0 (2024) |
| Relypsa, Inc. | $1,056 | 87 | $0 (2020) |
| Fresenius USA Marketing, Inc. | $988.84 | 89 | $0 (2024) |
| OPKO Pharmaceuticals, LLC | $620.11 | 52 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $478.81 | 27 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $356.45 | 19 | $0 (2023) |
| Vifor Pharma, Inc. | $338.00 | 24 | $0 (2023) |
| GlaxoSmithKline, LLC. | $333.94 | 17 | $0 (2024) |
| GENZYME CORPORATION | $297.37 | 9 | $0 (2023) |
| Otsuka America Pharmaceutical, Inc. | $280.40 | 14 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $674.15 | 36 | Fresenius USA Marketing, Inc. ($134.27) |
| 2023 | $1,035 | 51 | Travere Therapeutics, Inc. ($153.60) |
| 2022 | $1,231 | 73 | OPKO Pharmaceuticals, LLC ($227.74) |
| 2021 | $1,526 | 104 | Fresenius USA Marketing, Inc. ($267.40) |
| 2020 | $902.43 | 52 | Relypsa, Inc. ($269.83) |
| 2019 | $1,140 | 93 | Relypsa, Inc. ($402.71) |
| 2018 | $1,222 | 82 | Relypsa, Inc. ($235.35) |
| 2017 | $991.76 | 62 | Amgen Inc. ($219.91) |
All Payment Transactions
553 individual payment records from CMS Open Payments — Page 1 of 23
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: Nephrology | ||||||
| 12/04/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $22.60 | General |
| Category: Nephrology | ||||||
| 11/19/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $24.78 | General |
| 11/19/2024 | CALLIDITAS THERAPEUTICS US INC. | TARPEYO (Drug) | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: Nephrology | ||||||
| 11/19/2024 | Amgen Inc. | KRYSTEXXA (Biological) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/10/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $26.37 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/08/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: Diabetes | ||||||
| 09/19/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $22.17 | General |
| Category: NEPHROLOGY | ||||||
| 09/16/2024 | GlaxoSmithKline, LLC. | BENLYSTA (Biological) | Food and Beverage | In-kind items and services | $22.78 | General |
| Category: IMMUNOLOGY | ||||||
| 09/04/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Education | In-kind items and services | $14.72 | General |
| Category: NEPHROLOGY | ||||||
| 08/29/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $20.78 | General |
| Category: Phosphate binder for ESRD | ||||||
| 08/22/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $22.19 | General |
| 08/08/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $24.02 | General |
| Category: Inflammation | ||||||
| 08/05/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $18.30 | General |
| Category: Phosphate binder for ESRD | ||||||
| 07/30/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Phosphate binder for ESRD | ||||||
| 07/10/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $19.75 | General |
| Category: Bone Health | ||||||
| 07/09/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $20.17 | General |
| Category: Diabetes | ||||||
| 07/02/2024 | Fresenius USA Marketing, Inc. | Velphoro (Drug) | Food and Beverage | In-kind items and services | $17.05 | General |
| Category: Phosphate binder for ESRD | ||||||
| 06/06/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $20.81 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/27/2024 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: Diabetes | ||||||
| 05/15/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.67 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/09/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: IMMUNOLOGY | ||||||
| 05/08/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $18.70 | General |
| 05/02/2024 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $16.93 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 05/01/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $9.06 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 31 | 2,059 | 43,386 | $1.3M | $601,772 |
| 2022 | 30 | 1,926 | 28,767 | $928,111 | $454,295 |
| 2021 | 29 | 2,170 | 43,482 | $1.0M | $520,985 |
| 2020 | 31 | 2,289 | 34,780 | $1.1M | $515,061 |
Total Patients
8,444
Total Services
150,415
Medicare Billing
$2.1M
Procedure Codes
121
All Medicare Procedures & Services
121 procedure records from CMS Medicare Utilization — Page 1 of 5
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 72 | 333 | $159,840 | $107,012 | 66.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 80 | 5,520 | $193,200 | $99,305 | 51.4% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2023 | 14 | 8,191 | $122,865 | $64,576 | 52.6% |
| J1306 | Injection, inclisiran, 1 mg | Office | 2023 | 16 | 5,680 | $124,960 | $53,383 | 42.7% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 267 | 736 | $77,280 | $50,121 | 64.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 290 | 495 | $100,350 | $39,443 | 39.3% |
| 90966 | Home dialysis services per month (20 years or older) | Office | 2023 | 16 | 117 | $56,160 | $30,013 | 53.4% |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | Office | 2023 | 11 | 1,100 | $88,000 | $28,863 | 32.8% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 134 | 163 | $43,720 | $24,379 | 55.8% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 47 | 4,057 | $73,066 | $23,287 | 31.9% |
| 90935 | Hemodialysis procedure with physician evaluation | Facility | 2023 | 123 | 215 | $38,700 | $13,156 | 34.0% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2023 | 29 | 42 | $20,160 | $11,265 | 55.9% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 60 | 147 | $36,750 | $8,157 | 22.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 165 | 610 | $24,555 | $7,709 | 31.4% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 32 | 56 | $16,800 | $6,636 | 39.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 113 | 122 | $18,300 | $6,303 | 34.4% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 21 | 14,791 | $29,582 | $5,850 | 19.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $10,720 | $5,420 | 50.6% |
| 90945 | Dialysis procedure including 1 evaluation | Facility | 2023 | 20 | 69 | $12,420 | $5,056 | 40.7% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 56 | 62 | $10,000 | $2,879 | 28.8% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 32 | 79 | $7,900 | $1,983 | 25.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 139 | 220 | $2,420 | $1,848 | 76.4% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 22 | 42 | $3,780 | $1,405 | 37.2% |
| 80069 | Kidney function blood test panel | Office | 2023 | 118 | 152 | $4,560 | $1,294 | 28.4% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 12 | 12 | $960.00 | $863.16 | 89.9% |
About Dr. Dennis Phan, MD
Dr. Dennis Phan, MD is a Nephrology healthcare provider based in Salinas, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/02/2006. The National Provider Identifier (NPI) number assigned to this provider is 1437238342.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dennis Phan, MD has received a total of $8,722 in payments from pharmaceutical and medical device companies, with $674.15 received in 2024. These payments were reported across 553 transactions from 41 companies. The most common payment nature is "Food and Beverage" ($8,053).
As a Medicare-enrolled provider, Phan has provided services to 8,444 Medicare beneficiaries, totaling 150,415 services with total Medicare billing of $2.1M. Data is available for 4 years (2020–2023), covering 121 distinct procedure/service records.
Ad
Practice Information
- Specialty Nephrology
- Location Salinas, CA
- Active Since 11/02/2006
- Last Updated 03/07/2023
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1437238342
Products in Payments
- Veltassa (Drug) $1,394
- Velphoro (Drug) $938.19
- Parsabiv (Drug) $511.32
- RAYALDEE (Drug) $468.70
- Kerendia (Drug) $356.45
- LOKELMA (Drug) $355.07
- BENLYSTA (Biological) $333.94
- KRYSTEXXA (Biological) $286.47
- Rituxan (Biological) $278.58
- ACTHAR (Biological) $273.92
- JYNARQUE (Drug) $251.02
- LUPKYNIS (Drug) $234.49
- Aranesp (Biological) $209.80
- Prolia (Biological) $175.95
- INJECTAFER (Drug) $170.08
- TARPEYO (Drug) $135.79
- Rayaldee (Drug) $135.66
- THYMOGLOBULIN (Drug) $125.00
- FARXIGA (Drug) $123.74
- IBSRELA (Drug) $91.32
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.